Monkeypox Diagnosis and Treatment Market

Global Monkeypox Diagnosis & Treatment Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2024-2030: Increasing prevalence, technological advancements, increasing demand for specificity in diagnosis as well as treatment at global level is providing kick start for growth of the Monkeypox diagnosis and treatment market.

Global Monkeypox Diagnosis & Treatment Market is valued at USD XX Billion in 2024 and it is expected to reach USD XX Billion by 2030 with a CAGR of XX% over the forecast period.

Scope of Global Monkeypox Diagnosis & Treatment Market:

Monkeypox is an infectious disease caused by monkeypox virus (MPXV). This virus is mostly endemic in densely forested regions of west, central and east Africa. In that also, the presence is more particularly in the northern and central regions of the Democratic Republic of the Congo. Out of total 26 provinces of Democratic Republic of the Congo, 11 are identified as endemic for monkeypox. According to WHO, the cases are expanding in other 22 provinces as of November, 2023. For instance, from 1^st January, 2022 to 22^nd June, 2022, total 3413 laboratory confirmed cases were reported and one death was reported to WHO from 50 countries.

Monkeypox virus was originated in 1958 during an outbreak among monkeys in Danish laboratory. After 12 years to the discovery of virus, first case was reported in a human in a 9 months old infant in the Democratic Republic of the Congo. In the initial phase this disease was a rare but serious zoonotic disease. The first outbreak outside South Africa occurred in 2003 and the most recent outbreak occurred in 2022 which was surprising for global public health authorities.

For treating the disease before going to death causing stage, early detection of monkeypox plays a crucial role. For detection of disease, different diagnostic tests are available in the market. As it is an infectious disease which spreads through close contact with the infected person, there is necessity of some preventive measures also. And for prevention of the disease, vaccine is available in the market. As per the recent outbreak in 2022, the market for diagnosis as well as preventive measures such as vaccines is evolving.

Revenue Generation Model:

The revenue generation model for monkeypox disease is based on the sale of diagnostic kits, vaccines to healthcare providers such as hospitals, clinics, diagnostic labs. The companies providing the vaccines generate their revenue through research and development, patent filings, manufacturing and distributing these vaccines to end users including patients as well as healthcare providers.

Supply Chain Analysis:

The supply chain analysis for monkeypox market involves various steps involved in manufacturing and distribution of diagnostic kits as well as vaccines from raw materials to end-users. The supply chain typically involves manufacturers, suppliers, distributors and retailers. Companies manufacturing vaccines receive the material required for production of vaccines from suppliers and the vaccines are manufactured. After manufacturing, the vaccines are distributed through different distributors and retailers to end-users.

Value Chain Analysis:

The value chain analysis model involves the identification of components which add value to the production and distribution of vaccines. The value chain particularly involves research and development, manufacturing, marketing and distribution of vaccines. As a preventive measure, vaccines market is growing in a different manner and hence companies are investing more in research and devlopment of vaccines. The companies conduct research on the vaccinating molecules and then manufacture the vaccines and then it comes to marketing and distribution of the vaccines.

COVID-19 Impact:

COVID-19 was an large outbreak declared by WHO on 11^th March, 2020. This disease has disturbed everything including healthcare services. As the number of patients were increasing day by day, the healthcare systems were not sufficient to provide the facility to the patients. Monkeypox was also an outbreak from year 2022. And the outbreak was majorly impacting in African region which is economically weakest region. Also, these exhausted healthcare systems were unable to serve for the patients of monkeypox. Lack of diagnostic laboratories, availability of antiviral medicines, vaccines were the factors impacting the management of monkeypox.

Due to having such a large outbreak, the monkeypox disease management was got ignored regarding provision of diagnostic services, treatment services including medicines as well as vaccines, follow-up services.

For instance in August, 2022, African countries faced some other challenges during the period of COVID-19. Some of them were lack of awareness and information about monkeypox disease along with lack of healthcare facilities and shortage of trained healthcare professionals.

Key Market Players:

Prominent key players for Monkeypox diagnosis and treatment maket include pharmaceutical and biotechnological products manufacturing companies such as Bavarian Nordic, Geovax Labs, Inovio Pharmaceuticals, Valneva SE, Nanoviricides, Inc., Altimmune Inc., Abbott Laboratories, Biorad Laboratories, Thermo Fisher Scientific, QIAGEN, Cepheid, Roche Diagnostics, Biomérieux, Genmark Diagnostics, Luminex Corporation, ACON Biotech, Altona Diagnostics, Bioperfectus Technologies, Daan Gene, Shanghai ZJ Bio-Tech Co., Ltd., NOVACYT, Perkin Elmer, Sansure Biotech, TIB Molbiol. Some of these companies are manufacturers of vaccines and some of these are manufacturers of diagnosis kits for monkeypox disease. Some players are also involved in research and development of monkeypox treatment.

Driving Factors:

Increasing prevalence is providing fuel for the growth of Monkeypox diagnosis & treatment market:

Monkeypox is an infectious disease caused by monkeypox virus which is transmitted by close contact with the infected person. Although the first case was observed in 1970, tafter very long period of time the outbreak was observed recently in 2022. The outbreak appeared suddenly and spread rapidly across Europe, America. Total 110 countries reported 87000 cases and 112 deaths. And the number of cases were more in the African region. 2672 confirmed cases were reported from UK in August 2022. Also, the monkeypox caused by Clade-I virus, affects badly and lead to death of the person.

So, the severity of the disease is more and as it is a transmissable disease by touch, the spread of disease occurs rapidly. The numbers are also indicating the need of early diagnosis of monkeypox and proper treatment for the same. For fulfilling this need, there is necessity of development and manufacturing of diagnostic kits, medicines and vaccines as well. These factors are the accelerating elements for the growth of monkeypox market.

Restraining Factor:

Increased focus on research & development is acting as a value adding element in Monkeypox diagnosis & treatment:

As per the outbreak observed in 2022, the companies came to know about the severity of disease and the speed with which the disease spreads. To reduce the burden of disease, there is necessity for early diagnosis and treatment for monkeypox. Currently, no specific medication is available for monkeypox. The available particulars for monkeypox include some diagnostic kits and vaccines. For instance, in 2022, Oxford university contributed to new UK research consortium to develop better diagnostic kits, potential therapies and vaccine effectiveness. Also, the consortium had invested US$2.16 million for the development of the particulars related to monkeypox. Recently in 2024, the National Institute for Health and Care Research (NIHR) had called valunteers for monkeypox vaccine trial. So, the diagnostic kits, vaccines, medications are underway to enter the market due to the contribution of agencies and pharmaceutical as well as biotechnology companies in research and development. Hence, the research and development in the area of monkeypox is working as a fuel to expand the market.

Limited awareness & complex diagnosis are creating obstacles in growing Monkeypox diagnosis & treatment market:

Monkeypox has a way long back history. And the re-emergence of the disease was observed in 2017 which was after a very long time. Due to this, the awareness regarding monkeypox was observed less. In 2022, when the outbreak of monkeypox observed, again the awareness was affected by COVID conditions. So, this is indicating the limitations regarding awareness of monkeypox.

Besides, along with that there are some diseases like smallpox and chickenpox which have similar symptoms as monkeypox. At the stage of diagnosis, it becomes complex to detect monkeypox appropriately. And hence, the delay in diagnosis impacts patient outcomes and demand for specific diagnostic tools. For instance, in August 2022, universities had taken initiatives regarding the awareness and preparedness of monkeypox among students.

Opportunity Factors:

Expansion in treatment options will create market growing opportunities: No specific treatment is available for monkeypox. But, as it is a virus innfected disease, anti-viral drugs are effective against monkeypox. Such drugs are being utilized for the treatment of monkeypox. Also, research and development is going on new therapeutic agents and additional therapies which would be specifically applicable for monkeypox. For instance, anti-viral drugs acting on smallpox such as Tecovirimat, Brincidofovir, Cidofovir were being tested on humans for monkeypox in August 2022. Thsese developments on existing as well as innovative drugs are creating opportunities for monkeypox market.

Market Trends:

Advancement in Technology: Recently, advancements have been done in diagnosis of monkeypox such as TaqMan probe technology targetting both clades of monkeypox, self-contained cartridge an alternative to traditional PCR. The assay methods are highly sensitive and specific. These advancements are directing monkeypox towards more specificity in diagnosis. For instance, in 2022, as like COVID-19, rapid PCR test was being developed by Northwestern University spinoff company for Monkeypox detection. Also, FDA provided emergency use authorization for the test.

Customer Trends:

Earlier the customers were not that aware about the disease. But after the outbreak observed in 2022, the awareness regarding monkeypox was increased. And by taking into consideration the severity and spread of disease, customers are demanding specific and proper diagnosis as well as treatment and preventive measures such as vaccines.

Market Competition Nature:

Collaborations: As per necessity and increasing demand for management of monkeypox, key players are collaborating with other companies for the development of diagnostic kits, medications as well as vaccines. In July 2022, Bavarian Nordic got monkeypox approval for smallpox vaccine by European Medicines Agency in collaboration with Danish biotech.

Development of new technologies: Market players have become more aware about monkeypox and its diagnosis and treatment. The awareness regarding specificity in detection of monkeypox is playing major role in development of new technologies. For example, GeneXpert has launched an assay method which has shown more speicificity, high sensitivity, negative predictive value and positive predictive value in suspected specimens irrespective of the type of specimen collected.

Geographical Analysis:

Technological developments, availability of healthcare infrastructure supported by second highest prevalence rate across the globe making Europe as a dominating region:

Europe is dominating with research and developments, technological advancements, increasing cases and quality healthcare infrastructure. After African regions, the cases of monkeypox were also observed in European region. Total 22,640 cases were reported from the region in 2022. Based on the number of cases, an atypical outbreak of mpox was declared in the WHO European Region in May 2022. As the number of cases were increasing, there was increase in demand for diagnosis as well as treatment.

Monkeypox has no specific medicine for treatment, the only vaccine available for monkeypox is of Bavarian Nordic which is based in Europe and had got approval for vaccine manufacturing from European Medicine Agency in 2022. Also, modifications in diagnosis kits for making it specific for monkeypox has also been done in Europe. Increasing number of cases, having proficient healthcare infrastructure, contineous research and development for new diagnostic ways as well as treatments, all these factors are accelerating the growth of monkeypox diagnosis and treatment market in Europe.

Increasing need of diagnosis as well as treatment due to high prevalence rate makes Africa as second dominating region:

Increasing cases as well as outbreak observed in 2022 makes Africa a second dominating region for growth of Monkeypox diagnosis & treatment market. Monkeypox is an infectious disease caused by virus infection and mostly abundent in dense forest areas. As the outbreak was observed in 2022, most of the cases were from regions of west, central and east Africa. According to Africa CDC, in August 2022, 695 new cases were observed along with 17 new deaths. Out of total cases reported all over the world, most of the cases were from African region. These numbers are indicating the rate of disease spread in African region. The necessity of early detection as well as proper and specific treatment for monkeypox is more over there. This increasing demand is acting as fueling factor for the growth of diagnosis and treatment market for monkeypox.

Key Benefits of Monkeypox Diagnosis & Treatment Market:

• Global Monkeypox Diagnosis and Treatment Market report covers in-depth historical and forecast analysis.
• Global Monkeypox Diagnosis and Treatment Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country Level.
• Global Monkeypox Diagnosis and Treatment Market report helps to identify opportunities in the marketplace.
• Global Monkeypox Diagnosis and Treatment Market report covers extensive analysis of emerging trends and competitive landscape.

Global Monkeypox Diagnosis and Treatment Market Segmentation:

By Virus Type

• Clade I
• Clade II

By Diagnosis Type

• Epidemiological Investigation
• Laboratory Tests
• Polymerase Chain Reaction Test
• Virus Isolation Test
• Serology
• Others

By Treatment Type

• Anti-viral Therapy
• Immunomodulatory Therapy
• Vaccination
• Wound Care

By Product Type

• Kits
• Real Time PCR Kits
• ELISA Kits
• Vaccines
• Medications

By Age-Group

• Pediatric
• Adult
• Geriatric

By Gender

• Male
• Female

By End-User

• Hospitals & Clinics
• Diagnostic Labs
• Research Institutes
• Other

 By Regional & Country Level

• North America
  • S.
  • Canada
• Europe
  • K.
  • France
  • Germany
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa